S&P 500   3,630.03 (-0.15%)
DOW   29,958.64 (-0.29%)
QQQ   295.38 (+0.31%)
MSFT   214.95 (+0.51%)
NVDA   520.85 (+0.49%)
BABA   276.44 (-1.26%)
CGC   26.55 (-1.56%)
GE   10.58 (+1.24%)
MU   64.24 (+0.45%)
T   29.30 (+0.24%)
NIO   49.73 (-7.06%)
F   9.25 (-2.12%)
ACB   8.95 (-3.03%)
NFLX   484.19 (+0.27%)
GILD   60.66 (+0.68%)
BA   217.94 (-0.25%)
DIS   150.48 (-0.67%)
S&P 500   3,630.03 (-0.15%)
DOW   29,958.64 (-0.29%)
QQQ   295.38 (+0.31%)
MSFT   214.95 (+0.51%)
NVDA   520.85 (+0.49%)
BABA   276.44 (-1.26%)
CGC   26.55 (-1.56%)
GE   10.58 (+1.24%)
MU   64.24 (+0.45%)
T   29.30 (+0.24%)
NIO   49.73 (-7.06%)
F   9.25 (-2.12%)
ACB   8.95 (-3.03%)
NFLX   484.19 (+0.27%)
GILD   60.66 (+0.68%)
BA   217.94 (-0.25%)
DIS   150.48 (-0.67%)
S&P 500   3,630.03 (-0.15%)
DOW   29,958.64 (-0.29%)
QQQ   295.38 (+0.31%)
MSFT   214.95 (+0.51%)
NVDA   520.85 (+0.49%)
BABA   276.44 (-1.26%)
CGC   26.55 (-1.56%)
GE   10.58 (+1.24%)
MU   64.24 (+0.45%)
T   29.30 (+0.24%)
NIO   49.73 (-7.06%)
F   9.25 (-2.12%)
ACB   8.95 (-3.03%)
NFLX   484.19 (+0.27%)
GILD   60.66 (+0.68%)
BA   217.94 (-0.25%)
DIS   150.48 (-0.67%)
S&P 500   3,630.03 (-0.15%)
DOW   29,958.64 (-0.29%)
QQQ   295.38 (+0.31%)
MSFT   214.95 (+0.51%)
NVDA   520.85 (+0.49%)
BABA   276.44 (-1.26%)
CGC   26.55 (-1.56%)
GE   10.58 (+1.24%)
MU   64.24 (+0.45%)
T   29.30 (+0.24%)
NIO   49.73 (-7.06%)
F   9.25 (-2.12%)
ACB   8.95 (-3.03%)
NFLX   484.19 (+0.27%)
GILD   60.66 (+0.68%)
BA   217.94 (-0.25%)
DIS   150.48 (-0.67%)
Log in
NASDAQ:SHPG

Shire Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$179.20
0.00 (0.00 %)
(As of 01/8/2019)
Add
Compare
Today's Range
$179.20
Now: $179.20▼
$179.20
50-Day Range
$179.20
MA: $179.20▼
$179.20
52-Week Range
$123.73
Now: $179.20▼
$182.47
VolumeN/A
Average Volume2.21 million shs
Market Capitalization$54.71 billion
P/E Ratio11.83
Dividend Yield0.19%
Beta0.87
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
Read More
Shire logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.35 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SHPG
Previous Symbol
CUSIPN/A
CIK936402
Webwww.shire.com
Phone353-1609-6000
EmployeesN/A

Debt

Debt-to-Equity Ratio0.36
Current Ratio0.92
Quick Ratio0.51

Price-To-Earnings

Trailing P/E Ratio11.83
Forward P/E Ratio11.88
P/E Growth1.54

Sales & Book Value

Annual Sales$15.16 billion
Price / Sales3.61
Cash Flow$22.71 per share
Price / Cash Flow7.89
Book Value$119.43 per share
Price / Book1.50

Profitability

EPS (Most Recent Fiscal Year)$15.15
Net Income$4.27 billion
Net Margins30.63%
Return on Equity12.70%
Return on Assets7.06%

Miscellaneous

Outstanding Shares305,280,000
Market Cap$54.71 billion
Next Earnings DateN/A
OptionableOptionable

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Shire (NASDAQ:SHPG) Frequently Asked Questions

What stocks does MarketBeat like better than Shire?

Wall Street analysts have given Shire a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Shire wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Shire's earnings last quarter?

Shire plc (NASDAQ:SHPG) issued its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 earnings per share for the quarter, topping the Zacks' consensus estimate of $3.58 by $0.28. The biopharmaceutical company earned $3.77 billion during the quarter. Shire had a return on equity of 12.70% and a net margin of 30.63%. Shire's quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the firm posted $3.63 EPS.
View Shire's earnings history.

Who are some of Shire's key competitors?

Some companies that are related to Shire include Pfizer (PFE), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), AbbVie (ABBV), Novo Nordisk A/S (NVO), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), AstraZeneca (AZN), Eli Lilly and (LLY), Sanofi (SNY), Sanofi (SNY), Commonwealth Bank of Australia (CSLLY), GlaxoSmithKline (GSK) and Zoetis (ZTS).
View all competitors.

What other stocks do shareholders of Shire own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Gilead Sciences (GILD), Intel (INTC), (CELG), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), The Walt Disney (DIS), Johnson & Johnson (JNJ), Pfizer (PFE), Starbucks (SBUX) and Exxon Mobil (XOM).

Who are Shire's key executives?

Shire's management team includes the following people:
  • Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
  • Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
  • Gisele Dion, Chief Accounting Officer
  • Mr. Matthew Walker, Head of Technical Operations (Age 54)
  • Dr. Andreas Busch Ph.D., Head of R&D and Chief Scientific Officer (Age 55)

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

What is Shire's stock price today?

One share of SHPG stock can currently be purchased for approximately $179.20.

How big of a company is Shire?

Shire has a market capitalization of $54.71 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis.

What is Shire's official website?

The official website for Shire is www.shire.com.

How can I contact Shire?

Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.